Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.52 |
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
| ▸ | NMBR | P28336 | 2/20 | 0.48 |
| ▸ | GRPR | P30550 | 2/20 | 0.48 |
| ▸ | CALCR | P30988 | 4/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.44 |
| ▸ | GIPR | P48546 | 1/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018607 | 0.96 | F2 (0.51) | F2APLNRNMBRGRPRCALCR | |
| SCHEMBL25524938 | 0.92 | APLNR (0.44) | F2APLNRCALCRNMUR2NMUR1 | |
| SCHEMBL25524928 | 0.92 | APLNR (0.45) | F2APLNRCALCRNMUR2NMUR1 | |
| SCHEMBL25524956 | 0.91 | NMUR2 (0.51) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL25524962 | 0.90 | NMUR2 (0.46) | F2APLNRCALCRNMUR2NMUR1 | |
| SCHEMBL25524955 | 0.90 | NMUR2 (0.52) | F2NMBRGRPRCALCRNMUR2 | |
| SCHEMBL22019477 | 0.89 | NPY2R (0.44) | APLNRNMBRGRPRCALCRNMUR2 | |
| SCHEMBL25524960 | 0.89 | RAMP3 (0.46) | CALCR | |
| SCHEMBL25524949 | 0.88 | F2 (0.45) | F2CALCRHCRTR1HCRTR2GLP1R | |
| SCHEMBL22018604 | 0.88 | APLNR (0.45) | APLNRCALCRHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | YUYU PHARMA, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| WO-2020099925-A2 | PEPTIDES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE DISEASES | YUYU PHARMA, INC. (KR) | 2020-05-22 | — | — | WO | disclosed |
| US-20160244756-A1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146455-A1 | TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS | VIP, TSLP, IAPP | F2 780/4885APLNR 90/4885NMBR 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.